Pharmacy control in obesity telehealth

Control of fulfillment is becoming the key economic weapon in obesity telehealth. When a platform owns or tightly controls the pharmacy step, it can keep the patient in one checkout flow, secure branded supply faster, and capture more of the gross profit that would otherwise go to a third party dispenser. That matters because Numan is competing against US entrants that can combine prescribing, fulfillment, and manufacturer supply deals into one lower priced offer.

• Ro shows what this looks like in practice. A patient completes intake, gets reviewed by a clinician, and then the prescription is routed into NovoCare without leaving Ro's interface. Ro also operates six owned pharmacies, which lets it bundle consults, labs, dose changes, and drug shipping into one service instead of handing fulfillment to an outside chemist.
  2 sacra 4 biospace
• Manufacturer relationships matter because branded GLP-1 supply has been scarce and highly regulated. Novo Nordisk launched NovoCare Pharmacy in March 2025 at $499 per month for cash paying patients, and Eli Lilly built LillyDirect as a direct channel tied to third party mail order fulfillment. Platforms plugged into those channels can sell approved branded drugs while compounding gets squeezed.
  3 ro 4 biospace 5 globenewswire
• Hims & Hers used acquisition to buy this capability in Europe. Its June 2025 ZAVA deal added local operating infrastructure across the UK and major EU markets, and company filings show the deal closed in July 2025. That is a much faster route than building market by market pharmacy and prescribing compliance from scratch.
  1 sacra 6 hims

The next phase is a land grab for licensed pharmacy infrastructure and branded drug access in Europe. As US telehealth companies extend manufacturer linked, home delivery weight loss programs into the UK, local players will need stronger supply agreements, tighter pharmacy integration, or a care model that justifies charging more than a simpler drug access product.